Oncology (all articles)
ASTRO issues clinical guideline on external-beam radiation therapy for primary liver cancers.
19 Jan, 2022 | 08:36h | UTCOriginal Article: External Beam Radiation Therapy for Primary Liver Cancers: An ASTRO Clinical Practice Guideline – Practical Radiation Oncology
RCT: Prolonging prophylactic intravenous antibiotic regimens not beneficial after endoprosthetic reconstruction for lower extremity bone tumors.
19 Jan, 2022 | 08:37h | UTCCommentary: No Benefit Seen With Longer Antibiotic Course After Surgery for Bone Tumors – Cancer Therapy Advisor
M-A: Beta-blockers and renin–angiotensin system inhibitors may provide a modest benefit for the preservation of left ventricular function in patients with breast cancer treated with anthracyclines or trastuzumab.
19 Jan, 2022 | 08:34h | UTCA systematic review and meta-analysis of beta-blockers and renin–angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer – European Journal of Cardiology (link to abstract – $ for full-text)
Commentary: BBs, ACEI/ARBs to Prevent LV Dysfunction Due to Breast Cancer Drugs – American College of Cardiology
A single-arm study evaluated Naive T-Cell depleted peripheral blood stem-cell grafts for the prevention of chronic graft-versus-host disease.
19 Jan, 2022 | 08:22h | UTCNaive T-Cell Depletion to Prevent Chronic Graft-Versus-Host Disease – Journal of Clinical Oncology
Commentary: New graft strategy may improve outcomes for blood stem cell recipients – University of Pittsburg
M-A: Role of adjuvant therapy in esophageal cancer patients after neoadjuvant therapy and esophagectomy.
19 Jan, 2022 | 08:19h | UTCRole of Adjuvant Therapy in Esophageal Cancer Patients After Neoadjuvant Therapy and Esophagectomy: A Systematic Review and Meta-analysis – Annals of Surgery (link to abstract – $ for full-text)
Commentary on Twitter
New in Annals! Meta-analysis examines the effect of adjuvant therapy on overall survival after esophagectomy
Free download – https://t.co/r2SY34ZiVE
Lee, Samarasinghe, @michaelhylee, @luxmy_thiru, @ShargallYaron, Finley, @wc_hanna, Levine, Juergens, Agzarian pic.twitter.com/UV4v6leCcr
— Annals of Surgery (@AnnalsofSurgery) November 2, 2021
Dermatologic immune-related adverse events: the toxicity spectrum and recommendations for management.
19 Jan, 2022 | 08:15h | UTCRelated: Management of Dermatologic Adverse Events from Cancer Therapies
Prolonged follow-up of RCT: Emission Tomography–driven strategy in advanced Hodgkin Lymphoma.
19 Jan, 2022 | 08:16h | UTCPositron Emission Tomography–Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study – Journal of Clinical Oncology (link to abstract – $ for full-text)
Study shows many patients with metastatic cancer near the end of life still receive guideline-nonconcordant radiotherapy.
18 Jan, 2022 | 09:35h | UTCCommentary: Study: Cancer patients given high-dose radiation treatments even near end of life – UPI
Review: Imaging of prostate cancer.
18 Jan, 2022 | 09:20h | UTCImaging of Prostate Cancer – Deutsches Ärzteblatt International
Related:
ASCO Guideline: Optimum Imaging Strategies for Advanced Prostate Cancer
RCT: MRI can cut overdiagnoses in prostate-cancer screening by half.
Study: MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis
Review: The Use of MRI and PET Imaging Studies for Prostate Cancer Management
Cochrane Review: MRI Pathway vs. Systematic Biopsy for Detecting Prostate Cancer
Meta-analysis: Clinical Utility of MRI in the Decision-making Process Before Radical Prostatectomy
Research: MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis
Multiparametric MRI in the Detection of Clinically Significant Prostate Cancer
Adjuvant Capecitabine for early breast cancer: 15-year overall survival results from a randomized trial.
18 Jan, 2022 | 09:11h | UTC
RCT: Sirolimus plus prednisolone vs. sirolimus monotherapy for kaposiform hemangioendothelioma.
18 Jan, 2022 | 09:08h | UTCSirolimus plus prednisolone vs sirolimus monotherapy for kaposiform hemangioendothelioma: a randomized clinical trial – Blood (link to abstract – $ for full-text)
ASCO Guideline: Management of stage III non–small-cell lung cancer.
18 Jan, 2022 | 09:12h | UTCManagement of Stage III Non–Small-Cell Lung Cancer: ASCO Guideline – Journal of Clinical Oncology
RCT: Paclitaxel and Carboplatin noninferior to Paclitaxel and Ifosfamide in patients with carcinosarcoma of the uterus or ovary.
18 Jan, 2022 | 09:10h | UTCRandomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)
Artificial intelligence for diagnosis and Gleason grading of prostate cancer: the PANDA challenge.
16 Jan, 2022 | 22:41h | UTCCommentary: Large international evaluation shows AI accurately diagnoses prostate cancer – Karolinska Institutet
Commentary from one of the authors on Twitter (thread – click for more)
Honored to be part of the recently published study in Nature Medicine on the global #AI competition PANDA as a member of the @Google team and an expert panel of 6 US and Canadian Uropathologists. Check out this thread for my 5 top takeaways 👇#pathology #PathTwitter
— Dr. Mahul Amin (@DrMahul) January 14, 2022
U.S. Cancer statistics, 2022.
16 Jan, 2022 | 22:39h | UTCCancer statistics, 2022 – CA: A Cancer Journal for Clinicians
RCT: Nivolumab plus chemotherapy improved progression-free survival, but not overall survival, compared to placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer.
16 Jan, 2022 | 22:38h | UTCNivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Hallmarks of Cancer: New Dimensions.
14 Jan, 2022 | 08:12h | UTCHallmarks of Cancer: New Dimensions – Cancer Discovery
Commentary on Twitter
Just published! We proudly present "Hallmarks of Cancer: New Dimensions" by Douglas Hanahan, the third update to the seminal series. https://t.co/bSer4maIjF @Ludwig_Cancer pic.twitter.com/k8S6OT3nuo
— Cancer Discovery (@CD_AACR) January 12, 2022
Preliminary findings from a randomized trial showed promising results from dual PD-1 and HER2 blockade in HER2-positive gastric cancer.
14 Jan, 2022 | 08:03h | UTCThe KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer – Nature
Commentary on Twitter
Nature research paper: Combining immunotherapy with chemotherapy and targeted agents has the potential to improve the outcome of patients with advanced HER2-positive gastric tumours https://t.co/CNAgZObuTS pic.twitter.com/FWGwQzf4ze
— nature (@Nature) December 15, 2021
Review: Tumor burden and efficacy of immune-checkpoint inhibitors.
14 Jan, 2022 | 07:48h | UTCTumour burden and efficacy of immune-checkpoint inhibitors – Nature Reviews Clinical Oncology (if the link is paywalled, try this one)
Year in cardiovascular medicine: cardio-oncology 2020–21.
13 Jan, 2022 | 08:28h | UTCYear in cardiovascular medicine: cardio-oncology 2020–21 – European Heart Journal
ASCO Guideline Update: Adjuvant Therapy for Stage II Colon Cancer.
13 Jan, 2022 | 08:19h | UTCAdjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update – Journal of Clinical Oncology
Systematic Review: Chemotherapy for the treatment of oral cavity and oropharyngeal cancer.
13 Jan, 2022 | 08:14h | UTCSummary: Chemotherapy for mouth and throat cancer – Cochrane Library
Final overall survival analysis of the HER2CLIMB RCT: Tucatinib vs. placebo added to Trastuzumab and Capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases.
13 Jan, 2022 | 08:12h | UTCTucatinib vs Placebo Added to Trastuzumab and Capecitabine for Patients with Pretreated HER2+ Metastatic Breast Cancer with and without Brain Metastases (HER2CLIMB): Final Overall Survival Analysis – Annals of Oncology (link to abstract – $ for full-text)
Original Study: Randomized Trial: Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
RCT: In patients with untreated advanced melanoma, treatment with Relatlimab plus Nivolumab was associated with increased median progression-free survival compared with Nivolumab alone (10.1 months vs. 4.6 months).
12 Jan, 2022 | 08:43h | UTCRelatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
The inhibition of two immune checkpoints, LAG-3 and PD-1, provided a greater benefit with regard to PFS than inhibition of PD-1 alone in patients with previously untreated metastatic or unresectable melanoma. https://t.co/idtOgksg74 pic.twitter.com/vx1W9O4Dh6
— NEJM (@NEJM) January 5, 2022
European Guidelines on non–muscle-invasive bladder cancer (Ta, T1, and Carcinoma in Situ).
12 Jan, 2022 | 08:32h | UTC